Source:http://linkedlifedata.com/resource/pubmed/id/10541952
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
11
|
| pubmed:dateCreated |
1999-12-2
|
| pubmed:abstractText |
We report on a pair of male monozygotic twins, one unaffected and the other affected with gonadotropin-releasing hormone (GnRH)-dependent precocious puberty, and discuss the role of treatment with a GnRH analog in the attainment of full height potential in GnRH-dependent precocious puberty. At 1.6 years of age, the affected twin was studied for tall stature (+3.8 SD), and was diagnosed as having GnRH-dependent precocious puberty due to a hypothalamic hamartoma of the tuber cinereum. He was treated with oral cyproterone acetate (110-170 mg/m(2) daily) from 1.8 through 5. 0 years of age, with oral cyproterone acetate and intranasal buserelin acetate (700-900 microg/m(2) daily) from 5.0 through 7.5 years, and with intranasal buserelin acetate alone (1100- 1400 microg/m(2) daily) from 7.5 through 12.6 years. He attained a final height of 171.0 cm at 14.9 years of age (+0.10 SD) and his twin 170. 0 cm at 15.3 years of age (-0.10 SD), with their target height being 174.5 +/- 9.0 cm. CONCLUSION: This study indicates that GnRH analog treatment may preserve near full height potential in some patients with GnRH-dependent precocious puberty.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Nov
|
| pubmed:issn |
0340-6199
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
158
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
933-5
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:10541952-Administration, Inhalation,
pubmed-meshheading:10541952-Administration, Oral,
pubmed-meshheading:10541952-Body Height,
pubmed-meshheading:10541952-Buserelin,
pubmed-meshheading:10541952-Child, Preschool,
pubmed-meshheading:10541952-Cyproterone Acetate,
pubmed-meshheading:10541952-Drug Therapy, Combination,
pubmed-meshheading:10541952-Follow-Up Studies,
pubmed-meshheading:10541952-Gonadotropin-Releasing Hormone,
pubmed-meshheading:10541952-Growth Disorders,
pubmed-meshheading:10541952-Hamartoma,
pubmed-meshheading:10541952-Humans,
pubmed-meshheading:10541952-Hypothalamic Diseases,
pubmed-meshheading:10541952-Magnetic Resonance Imaging,
pubmed-meshheading:10541952-Male,
pubmed-meshheading:10541952-Progesterone Congeners,
pubmed-meshheading:10541952-Puberty, Precocious,
pubmed-meshheading:10541952-Treatment Outcome,
pubmed-meshheading:10541952-Twins, Monozygotic
|
| pubmed:year |
1999
|
| pubmed:articleTitle |
Treatment with a gonadotropin-releasing-hormone analog and attainment of full height potential in a male monozygotic twin with gonadotropin-releasing hormone-dependent precocious puberty.
|
| pubmed:affiliation |
Department of Pediatrics, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 60-8582, Japan. t-ishii@med.keio.ac.jp
|
| pubmed:publicationType |
Journal Article,
Case Reports,
Research Support, Non-U.S. Gov't
|